{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:02:54Z","timestamp":1790701374053,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2025ZZTS0892"],"award-info":[{"award-number":["2025ZZTS0892"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32300528"],"award-info":[{"award-number":["32300528"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","award":["2023RC3080"],"award-info":[{"award-number":["2023RC3080"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2026JJ90239"],"award-info":[{"award-number":["2026JJ90239"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Advances"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.biotechadv.2026.109028","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:52Z","timestamp":1788307252000},"page":"109028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Generative AI-enabled neoantigen vaccine engineering: From tumor antigen discovery to personalized construct design and translational validation"],"prefix":"10.1016","volume":"93","author":[{"given":"Xinjie","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haodong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biotechadv.2026.109028_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","article-title":"Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction","volume":"46","author":"Abelin","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/bioinformatics\/btv639","article-title":"Gapped sequence alignment using artificial neural networks: application to the MHC class I system","volume":"32","author":"Andreatta","year":"2016","journal-title":"Bioinformatics"},{"issue":"9","key":"10.1016\/j.biotechadv.2026.109028_bb0015","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0020","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1126\/science.aay9547","article-title":"Algorithms on regulatory lockdown in medicine","volume":"366","author":"Babic","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-4939-7537-2_14","article-title":"Mass spectrometry based immunopeptidomics for the discovery of cancer neoantigens","volume":"1719","author":"Bassani-Sternberg","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0030","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005725","article-title":"Deciphering HLA-I motifs across HLA peptidomes improves neoantigen predictions and identifies allostery regulating HLA specificity","volume":"13","author":"Bassani-Sternberg","year":"2017","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of antigen processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0050","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nbt.4313","article-title":"Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification","volume":"37","author":"Bulik-Sullivan","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0065","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.3390\/ijms231710131","article-title":"Sources of Cancer neoantigens beyond single-nucleotide variants","volume":"23","author":"Capietto","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0070","doi-asserted-by":"crossref","first-page":"82","DOI":"10.37349\/ei.2023.00091","article-title":"Beyond MHC binding: immunogenicity prediction tools to refine neoantigen selection in cancer patients","volume":"3","author":"Carri","year":"2023","journal-title":"Explor Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0075","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14760584.2021.1935248","article-title":"Challenges targeting cancer neoantigens in 2021: a systematic literature review","volume":"20","author":"Chen","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006061","article-title":"MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia","volume":"5","author":"Cobbold","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature22383","article-title":"Quantifiable predictive features define epitope-specific T cell receptor repertoires","volume":"547","author":"Dash","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0090","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.annonc.2020.05.008","article-title":"Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO precision medicine working group","volume":"31","author":"De Mattos-Arruda","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1128326","article-title":"Performance comparison of TCR-pMHC prediction tools reveals a strong data dependency","volume":"14","author":"Deng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0105","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/978-1-0716-3646-6_23","article-title":"Mass spectrometry-based Immunopeptidomics of peptides presented on human leukocyte antigen proteins","volume":"2758","author":"ElAbd","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0110","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1109\/TPAMI.2021.3095381","article-title":"ProtTrans: toward understanding the language of life through self-supervised learning","volume":"44","author":"Elnaggar","year":"2022","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0115","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0120","first-page":"563","article-title":"A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types","volume":"2","author":"Gartner","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0125","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0130","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3389\/fimmu.2018.01716","article-title":"Predicting antigen presentation-what could we learn from a million peptides?","volume":"9","author":"Gfeller","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0135","doi-asserted-by":"crossref","DOI":"10.2196\/30545","article-title":"Algorithm change protocols in the regulation of adaptive machine learning-based medical devices","volume":"23","author":"Gilbert","year":"2021","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1014256","article-title":"On TCR binding predictors failing to generalize to unseen peptides","volume":"13","author":"Grazioli","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0145","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: past, present, and future","volume":"119","author":"Guo","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0150","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","article-title":"Exploiting tumor neoantigens to target Cancer evolution: current challenges and promising therapeutic approaches","volume":"11","author":"Gupta","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/2326-6066.CIR-13-0022","article-title":"Getting personal with neoantigen-based therapeutic cancer vaccines","volume":"1","author":"Hacohen","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0160","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/eji.201141774","article-title":"Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity","volume":"42","author":"Harndahl","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00251-008-0341-z","article-title":"NetMHCpan, a method for MHC class I binding prediction beyond humans","volume":"61","author":"Hoof","year":"2009","journal-title":"Immunogenetics"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0170","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41587-023-02115-w","article-title":"Generative models for protein structures and sequences","volume":"42","author":"Hsu","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0175","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkad1068","article-title":"The SysteMHC atlas v2.0, an updated resource for mass spectrometry-based immunopeptidomics","volume":"52","author":"Huang","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0180","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0185","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","article-title":"pVACtools: a computational toolkit to identify and visualize cancer neoantigens","volume":"8","author":"Hundal","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1008814","article-title":"Predicting recognition between T cell receptors and epitopes with TCRGP","volume":"17","author":"Jokinen","year":"2021","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/imm.12160","article-title":"NetMHCstab - predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery","volume":"141","author":"J\u00f8rgensen","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0200","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0205","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0210","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness-a literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0220","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0225","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0230","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0235","article-title":"Improving MHC class I antigen-processing predictions using representation learning and cleavage site-specific kernels","volume":"2","author":"Lawrence","year":"2022","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0240","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41467-026-68651-6","article-title":"NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes","volume":"17","author":"Lee","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0245","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011366","article-title":"PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development","volume":"13","author":"Lemke","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0250","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41592-025-02910-0","article-title":"Assessment of computational methods in predicting TCR-epitope binding recognition","volume":"23","author":"Lu","year":"2026","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0255","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkn202","article-title":"NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11","volume":"36","author":"Lundegaard","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0260","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41587-022-01618-2","article-title":"Large language models generate functional protein sequences across diverse families","volume":"41","author":"Madani","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0265","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1101\/gr.170753.113","article-title":"T-cell receptor repertoires share a restricted set of public and abundant CDR3 sequences that are associated with self-related immunity","volume":"24","author":"Madi","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0270","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002071","article-title":"HLA ligand atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy","volume":"9","author":"Marcu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0275","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-23-0158","article-title":"The neo-open Reading frame peptides that comprise the tumor Framome are a rich source of neoantigens for cancer immunotherapy","volume":"12","author":"Martin","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0280","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0285","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm6359","article-title":"Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neoantigens in patients with lung cancer","volume":"8","author":"Merlotti","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0295","doi-asserted-by":"crossref","first-page":"13217","DOI":"10.3390\/ijms232113217","article-title":"What are the reasons for continuing failures in Cancer therapy? Are misleading\/inappropriate preclinical assays to be blamed? Might some modern therapies cause more harm than benefit?","volume":"23","author":"Mirzayans","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0300","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0305","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.trecan.2024.07.009","article-title":"CD4(+) T cells in antitumor immunity","volume":"10","author":"Montauti","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0310","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa318","article-title":"Current challenges for unseen-epitope TCR interaction prediction and a new perspective derived from image classification","volume":"22","author":"Moris","year":"2021","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0315","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","article-title":"Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction","volume":"56","author":"M\u00fcller","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0320","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-016-0288-x","article-title":"NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets","volume":"8","author":"Nielsen","year":"2016","journal-title":"Genome Med."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0325","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1110\/ps.0239403","article-title":"Reliable prediction of T-cell epitopes using neural networks with novel sequence representations","volume":"12","author":"Nielsen","year":"2003","journal-title":"Protein Sci."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0330","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/bioinformatics\/bth100","article-title":"Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach","volume":"20","author":"Nielsen","year":"2004","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000796","article-title":"NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence","volume":"2","author":"Nielsen","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0340","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13073-016-0365-1","article-title":"Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?","volume":"8","author":"O\u2019Donnell","year":"2016","journal-title":"Genome Med."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0345","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cels.2018.05.014","article-title":"MHCflurry: open-source class I MHC binding affinity prediction","volume":"7","author":"O\u2019Donnell","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0350","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","article-title":"MHCflurry 2.0: improved Pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing","volume":"11","author":"O\u2019Donnell","year":"2020","journal-title":"Cell Syst."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2025.100938","article-title":"diaPASEF analysis for HLA-I peptides enables quantification of common cancer neoantigens","volume":"24","author":"Oliinyk","year":"2025","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0360","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fimmu.2015.00298","article-title":"Alternative antigen processing for MHC class I: multiple roads lead to Rome","volume":"6","author":"Oliveira","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0365","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100080","article-title":"Sensitive Immunopeptidomics by leveraging available large-scale multi-HLA spectral libraries, data-independent acquisition, and MS\/MS prediction","volume":"20","author":"Pak","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0375","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/vaccines12121341","article-title":"Challenges and new directions in therapeutic cancer vaccine development","volume":"12","author":"Pan","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0380","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.3389\/fimmu.2019.03151","article-title":"Major histocompatibility complex binding, eluted ligands, and immunogenicity: benchmark testing and predictions","volume":"10","author":"Paul","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0385","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0390","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1073\/pnas.1409155111","article-title":"Diversity and clonal selection in the human T-cell repertoire","volume":"111","author":"Qi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0395","doi-asserted-by":"crossref","first-page":"19414","DOI":"10.1073\/pnas.1010586107","article-title":"Convergent recombination shapes the clonotypic landscape of the naive T-cell repertoire","volume":"107","author":"Quigley","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0400","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1158\/1078-0432.CCR-10-2114","article-title":"Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines","volume":"17","author":"Respa","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0405","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0410","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-019-0666-2","article-title":"Best practices for bioinformatic characterization of neoantigens for clinical utility","volume":"11","author":"Richters","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0415","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2016239118","article-title":"Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences","volume":"118","author":"Rives","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0420","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0425","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0430","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0435","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0440","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","article-title":"A large peptidome dataset improves HLA class I epitope prediction across most of the human population","volume":"38","author":"Sarkizova","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0445","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13059-025-03763-8","article-title":"MHCquant2 refines immunopeptidomics tumor antigen discovery","volume":"26","author":"Scheid","year":"2025","journal-title":"Genome Biol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0450","article-title":"Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting","volume":"2","author":"Schmidt","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0455","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79854","article-title":"Generative power of a protein language model trained on multiple sequence alignments","volume":"12","author":"Sgarbossa","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0460","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/2326-6066.CIR-19-0464","article-title":"High-throughput prediction of MHC class I and II neoantigens with MHCnuggets","volume":"8","author":"Shao","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0465","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.immuni.2020.11.004","article-title":"SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors","volume":"53","author":"Shomuradova","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0470","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1074\/mcp.TIR119.001641","article-title":"Mass spectrometry based Immunopeptidomics leads to robust predictions of phosphorylated HLA class I ligands","volume":"19","author":"Solleder","year":"2020","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0475","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nsmb.3383","article-title":"Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8(+) T cell epitope","volume":"24","author":"Song","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0480","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3389\/fimmu.2020.01803","article-title":"Prediction of specific TCR-peptide binding from large dictionaries of TCR-peptide pairs","volume":"11","author":"Springer","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0485","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/pharmaceutics15020622","article-title":"mRNA-based therapeutics in cancer treatment","volume":"15","author":"Sun","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100116","article-title":"MS-based HLA-II Peptidomics combined with multiomics will aid the development of future immunotherapies","volume":"20","author":"Taylor","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0495","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00018-005-4528-2","article-title":"Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding","volume":"62","author":"Tenzer","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0500","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1038\/s41591-025-03983-2","article-title":"Generative artificial intelligence in medicine","volume":"31","author":"Teo","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0505","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1487378","article-title":"Neoantigen prioritization based on antigen processing and presentation","volume":"15","author":"Tokita","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0515","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41541-025-01258-y","article-title":"AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development","volume":"10","author":"Villanueva-Flores","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0520","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nbt.3932","article-title":"Neoantigen prediction and the need for validation","volume":"35","author":"Vitiello","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0525","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","article-title":"De novo design of protein structure and function with RFdiffusion","volume":"620","author":"Watson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0530","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0535","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0540","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.3389\/fimmu.2019.02559","article-title":"DeepHLApan: a deep learning approach for neoantigen prediction considering both HLA-peptide binding and immunogenicity","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0545","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0550","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumor mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0555","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","article-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses","volume":"25","author":"Yang","year":"2019","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.biotechadv.2026.109028_bb0560","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btae585","article-title":"NeoDesign: a computational tool for optimal selection of polyvalent neoantigen combinations","volume":"40","author":"Yu","year":"2024","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0565","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biotechadv.2026.109028_bb0570","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0575","doi-asserted-by":"crossref","DOI":"10.1126\/science.adr8470","article-title":"Deep generative models design mRNA sequences with enhanced translational capacity and stability","volume":"390","author":"Zhang","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.biotechadv.2026.109028_bb0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006457","article-title":"Systematically benchmarking peptide-MHC binding predictors: from synthetic to naturally processed epitopes","volume":"14","author":"Zhao","year":"2018","journal-title":"PLoS Comput. Biol."}],"container-title":["Biotechnology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073497502600234X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073497502600234X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:26:32Z","timestamp":1790699192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073497502600234X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":116,"alternative-id":["S073497502600234X"],"URL":"https:\/\/doi.org\/10.1016\/j.biotechadv.2026.109028","relation":{},"ISSN":["0734-9750"],"issn-type":[{"value":"0734-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generative AI-enabled neoantigen vaccine engineering: From tumor antigen discovery to personalized construct design and translational validation","name":"articletitle","label":"Article Title"},{"value":"Biotechnology Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biotechadv.2026.109028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109028"}}